Intelligence Profile
Research Papers
Research on low-dose aripiprazole is limited, but several studies and clinical trials have explored its effects and clinical applications in various contexts.
One study explored the effects of aripiprazole exposure in utero on rat skeletal development, revealing potential alterations in ossification (Anatomy & Cell Biology, 2026). This research highlights possible developmental concerns, although its direct applicability to humans is uncertain.
A clinical report described an adolescent with psychosis managed extensively by a multidisciplinary team, including aripiprazole use (Clinical Psychopharmacology and Neuroscience, 2026). This showcases the therapeutic potential of aripiprazole within a broader clinical framework, even though it was a singular case report.
In terms of safety, an article discussed a case of acute liver failure and hemolytic anemia induced by an overdose of aripiprazole and quetiapine in a patient with complex health conditions (Frontiers in Psychiatry, 2026). This underscores the importance of cautious dosing.
A notable investigation involved treating negative affect in low back pain patients (NCT04747314), although it’s unclear if aripiprazole was the primary focus. The trial completed phases 2 and 3, yet specific findings were not detailed.
Finally, a trial on the efficacy of antipsychotics, including aripiprazole, in schizophrenia (NCT00905307) aimed to compare newer antipsychotics with conventional options. Completed in phase 2, it provides some context for aripiprazole's role, though details are scarce.
Overall, while low-dose aripiprazole appears promising in several scenarios, detailed and robust human research is limited. Clinical application should proceed cautiously.
Disclaimer: This content is informational and not a substitute for professional medical advice.